Please assess the completion status of the following clinical trial:

Trial Title: To Evaluate the Safety and Efficacy of Sofosbuvir and Ribavirin in Patients With HCV (Genotype 3) Related Decompensated Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female ≥ 18 yrs~* Baseline HCV RNA \> 1000 IU/ml~* Cirrhosis with current or prior decompensation~* HCV (Hepatitis C Infection) Genotype 3~* Treatment naïve or treatment experienced~Exclusion Criteria:~* HIV or HBV (Hepatitis B Virus) co-infection~* Recent Variceal bleed~* Pregnancy~* Haemolytic anaemia~* Platelet counts \<20,000/ml~* Advanced HCC (Hepatocellular Carcinoma)~* Renal dysfunction, GFR (glomerular filtration rate) \< 30 ml/min~* Haemoglobin \< 10 g/dl~* MELD (Model for End Stage Liver Disease) \>25, CTP (Child-Turcotte-Pugh score) \>12~* Post organ transplant

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Sofosbuvir + Ribavirin 1 (Type: ACTIVE_COMPARATOR): Sofosbuvir + Ribavirin x 24 weeks
- Sofosbuvir + Ribavirin 2 (Type: EXPERIMENTAL): Sofosbuvir + Ribavirin x 36 weeks
- Sofosbuvir + Ribavirin 3 (Type: EXPERIMENTAL): Sofosbuvir + Ribavirin x 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).